膝悦颗粒(Xiyue Granules) - 在研适应症：膝关节滑膜炎_专利_临床

概要

基本信息

药物类型

中药

别名-

靶点-

作用机制-

治疗领域

皮肤和肌肉骨骼疾病

在研适应症

膝关节滑膜炎

非在研适应症-

原研机构-

在研机构

上海中医大源创科技有限公司

河南省正骨研究院

非在研机构-

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)临床3期

特殊审评-

登录后查看时间轴

关联

2

项与膝悦颗粒相关的临床试验

CTR20140310 / Active, not recruiting临床3期

膝悦颗粒治疗慢性膝关节滑膜炎的随机、双盲、安慰剂平行对照、多中心、Ⅲ期临床试验

以安慰剂为对照，进一步评价膝悦颗粒治疗慢性膝关节滑膜炎的有效性和安全性。

开始日期2014-04-14

申办/合作机构

上海中医大源创科技有限公司

[+1]

CTR20132439 / Completed临床2期

膝悦颗粒治疗慢性膝关节滑膜炎的随机、双盲、安慰剂平行对照并剂量探索多中心Ⅱ期临床试验

以安慰剂为对照，初步评价不同剂量膝悦颗粒治疗慢性膝关节滑膜炎的有效性和安全性。

开始日期2012-02-28

申办/合作机构

上海中医大源创科技有限公司

[+1]

100 项与膝悦颗粒相关的临床结果

登录后查看更多信息

100 项与膝悦颗粒相关的转化医学

登录后查看更多信息

100 项与膝悦颗粒相关的专利（医药）

登录后查看更多信息

2

项与膝悦颗粒相关的文献（医药）

2017-01-01·Evidence-Based Complementary and Alternative Medicine4区 · 医学

Efficacy of Combined XingZhi‐YiNao Granules and Hyperbaric Oxygen Therapy for Cognition and Motor Dysfunction in Patients with Delayed Encephalopathy after Acute Carbon Monoxide Poisoning

4区 · 医学

ArticleOA

作者: Mingjun, Bi ; Yong, Zou ; Jinglin, Wang ; Qin, Li ; Dadong, Guo ; Xiaoyu, Ding ; Li, Wang ; Meihua, Chu

Purpose. To investigate the efficacy of XingZhi‐YiNao (XZYN) granules and hyperbaric oxygenation (HBO) for cognition and motor dysfunction in patients with delayed encephalopathy after acute carbon monoxide poisoning (DEACMP). Methods. Eighty‐nine patients with DEACMP were randomly divided into control group (n = 19), HBO group (n = 32), and XZYN group (n = 38). All patients received conventional treatment. HBO group received HBO therapy once daily. XZYN group received extra XZYN granules plus HBO treatment. The related indexes including activity of daily living (ADL) scale, Montreal cognitive assessment (MoCA) scale, and mini mental state examination (MMSE) scale were measured. Cerebral white matter injury, age related white matter changes (ARWMC) scale, and the amplitude and latency of P300 were assessed. Results. Compared with control group, the neurological function scores of ADL, MoCA, and MMSE in HBO and XZYN groups were significantly improved, the impairment degree of brain white matter and cognition function were obviously alleviated, the latencies of P300 were significantly shortened, and the amplitudes of P300 were evidently increased (P < 0.05). Treatment efficacy of XZYN group was superior to that of HBO group (P < 0.05). Conclusion. Combined XZYN granules and HBO can significantly improve cognition and motor functions in patients with DEACMP.

2014-06-01·Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica

[Research of mechanism jinxueyuan granules increased saliva secretion of xerostomia model rats].

Article

作者: Qian, Xian ; Liu, Yan ; Wang, Hong-Yi

To analyze the specific mechanism of Jinxueyuan granules, the relationship between the Jinxueyuan granules increased the saliva secretion of xerostomia model SD rats and excitement of receptors were studied in this experiment. In the study, three groups of xerostomia model rats were successfully established by using M-receptor blockers-4-diphenyl-acetoxy-N-methyl-piperidine (4-DAMP) and atropine, or adrenergic receptor blocker phentolamine; after the modeling, the medicine Jinxueyuan granules were gavaged. According to the clinical dose of Jinxueyuan granules and SD rats body surface area, the rats in atropine group were divided three dose groups respectively, namely low, medium and high dose of Jinxueyuan granules groups. The 4-DAMP group and phentolamine group were gavaged medium dose of Jinxueyuan granules. And the amount of salivary secretion for 150 minutes in all groups continuously were measured, and the effect of Jinxueyuan granules increased salivation and the relationship between characteristics and the receptors were observed; and submandibular gland tissue of the rats was isolated, then the effect of Jinxueyuan Granules for expression of the water channel protein aquaporin-5 (AQP5) in submandibular gland cells was analyzed by the Western blot technology. It was found that the saliva secretion of Jinxueyuan Granules groups was increased significantly, and compared with the saline control group, phentolamine group, 4-DAMP group and atropine group, difference was significant, P < 0.05. There was no significant difference between the low-dose of Jinxueyuan granules group and the saline group, but the medium dose of Jinxueyuan granules group had a significant difference, compared with the saline group (P < 0.05). In the time distribution of increasing saliva secretion, there was a significant difference between the saline and Jinxueyuan granules group in the saliva secretion (P < 0.05). After administration of Jinxueyuan granules, the expression of AQP5 protein in the submandibular gland cells expressing of treatment groups was increased, and compared with the blocker groups, there was a significant difference, P < 0.05. Except the atropine group, there was no significant difference in Jinxueyuan granules relieving the inhibition induced by blocks in phentolamine group and 4-DAMP group, compared with the saline group. Compared the AQP5 expression in three blockers groups, there was no significant difference in the efficacy of Jinxueyuan granules between phentolamine group and 4-DAMP group; but there was a significant difference between the atropine group and other groups (P < 0.05). Therefore, it was considered that the mechanism of Jinxueyuan granules increasing saliva secretion (effectiveness of nourishing Yin and generating body fluid ) possibly through the pathway mediated by muscarinic M receptor, especially M3 receptor, or adrenergic receptor, and increased expression of salivary gland AQP5 membrane, and then stimulate saliva production.

100 项与膝悦颗粒相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
膝关节滑膜炎	临床3期	中国	上海中医大源创科技有限公司	2014-04-14
膝关节滑膜炎	临床3期	中国	河南省正骨研究院	2014-04-14